GRAIL reports third quarter 2026 financial results
FROM THE WIRE · PRNEWSWIRE.COM
FDA Advisory Committee Voted in Favor of Approval of GRAIL's Galleri Multi-Cancer Early Detection Test Q3 Galleri ® Test Volume Increased ~24% to More Than 56,000 Year-Over-Year, Year-to-Date Test Volume Increased ~36% to More Than 174,000 Q3 Galleri Revenue Grew 14%…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishThe FDA advisory committee voted in favor of approving Galleri, a relevant factor for the stock.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01The FDA advisory committee voted in favor of approving the Galleri test.
- 02Galleri test volume rose about 24% year over year in the third quarter, to more than 56,000.
- 03Q3 Galleri revenue grew 14% year over year to $37.3 million.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets